LPA
LPA encodes apolipoprotein(a), also written Apo(a) and known as lipoprotein(a), Lp(a) or LP. It is the main constituent of the Lp(a) particle and is a serine proteinase that inhibits tissue-type plasminogen activator. Browse Assay Genie's current range of LPA research reagents below, or read on for the biology behind the target.
Apolipoprotein(a) is the main constituent of lipoprotein(a), abbreviated Lp(a). The protein has serine proteinase activity and is capable of autoproteolysis. It inhibits the activity of tissue-type plasminogen activator, and Lp(a) may act as a ligand for megalin (Gp 330). The LPA gene therefore links a lipoprotein particle to the machinery that regulates fibrinolysis, which is why it is studied in both lipid biology and thrombosis research.
The LPA gene product belongs to the peptidase S1 family, plasminogen subfamily, and HGNC places the gene in two groups: serine proteases and kringle domain containing proteins. The number of kringle-type domains varies between individuals, with 2 to 43 copies reported. The allele used for the reference genome sequence carries 15 copies of the kringle-type repeats. This copy-number variation means the size of the encoded protein differs from one person to another, which is a useful point to keep in mind when interpreting LPA work in human samples.
According to the NCBI Gene summary, the encoded protein makes up a substantial portion of lipoprotein(a) and is proteolytically cleaved. The resulting fragments attach to atherosclerotic lesions and promote thrombogenesis. Elevated plasma levels of this protein are linked to atherosclerosis. HGNC records the previous names for the gene as lipoprotein and Lp(a), and the current approved name is lipoprotein(a). Researchers may also meet the abbreviations Apo(a), Lp(a) and LP when searching the literature for the LPA gene or the Apo(a) protein.
Elevated plasma levels of the LPA-encoded protein are linked to atherosclerosis, and its cleavage fragments attach to atherosclerotic lesions.
Apo(a) inhibits tissue-type plasminogen activator, and its fragments promote thrombogenesis, making LPA relevant to studies of clotting balance.
Apo(a) is the main constituent of Lp(a), so LPA underpins work on how this particle is assembled and behaves.
Individuals carry between 2 and 43 kringle-type copies, giving a clear basis for studying structural variation in LPA.
LPA encodes apolipoprotein(a), the main constituent of lipoprotein(a). The protein has serine proteinase activity, is capable of autoproteolysis and inhibits tissue-type plasminogen activator. Lp(a) may also be a ligand for megalin (Gp 330). Check the datasheet of any product for its validated reactivity.
The approved name is lipoprotein(a). UniProt calls the protein apolipoprotein(a), abbreviated Apo(a). Aliases include Lp(a) and LP, and HGNC lists the previous names as lipoprotein and Lp(a). The same names are used for the particle and for the gene product, so context matters when reading papers.
The LPA protein contains 2 to 43 copies of kringle-type domains depending on the individual, so its size varies between people. The reference genome allele has 15 copies. Elevated plasma levels of the protein are linked to atherosclerosis, which makes this variation relevant to study design.
Plasminogen-family proteins, the fibrinolysis regulator and candidate ligand receptor linked to Lp(a), plus other targets with similar gene symbols.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P08519; product specifications from Assay Genie datasheets.